W. Bryan Hubbard

healthcare system as expeditiously as possible and make all of their resources available to explore the extent to which we can operationalize Ibogaine medicine as quickly as possible.

And it's my hope and aspiration that we will see all of Native America join this effort before the end of this year.

Tribal sovereignty is an area of the law with which I am not familiar.

I would not be able to speak to the degree to which they could autonomously open a clinic.

The most immediate issue would be related to the creation of a supply chain because you have traveled through interstate commerce in the U.S.

states which theoretically restrict it.

However, there is one spectacular opportunity not just to expedite the creation of Ibogaine treatment access for Native America but for all of America.

And this gets into federal right to try legislation authored by former U.S.

Senator Kyrsten Sinema and signed by the president during his first administration in 2018.

And what federal right to try legislation or the law provides is that once any medication makes its way through phase one safety testing within the FDA's process and

then anyone with a life-threatening condition for which that medication is being developed can request treatment with that medication and obtain it from a willing prescriber.

What does that mean?

That means that as soon as Texas or as soon as one of the Native tribes effectively completes a Phase I safety study under the language of the law,

anyone who has a life-threatening condition for which this medication is being developed, first and foremost, opioid dependency, can go and request and get the treatment.

We have one complication.

Presently, the Drug Enforcement Administration

in keeping with the practice of many government agencies that use their arbitrary authority to interpret law, has asserted that federal right to try does not apply to Schedule I substances.

This means that based on not the language of the law, but on DEA's interpretation preference of that law,

Once Ibogaine clears through phase one, it would be disqualified for access under federal right to try because the DEA says that if schedule one substances were intended to be included, they would have been specifically listed in the legislation.

When Kirsten Sinema, the author of the bill, explained to them that the language is unambiguous and it says any medication, their response was insolence.